Literature DB >> 32114633

Oxycodone self-administration and withdrawal behaviors in male and female Wistar rats.

Adam Kimbrough1, Jenni Kononoff2, Sierra Simpson1,2, Marsida Kallupi1, Sharona Sedighim1, Kenia Palomino3, Dana Conlisk2, Jeremiah D Momper3, Giordano de Guglielmo1, Olivier George4.   

Abstract

RATIONALE: Over the last decade, oxycodone has become one of the most widely abused drugs in the USA. Oxycodone use disorder (OUD) is a serious health problem that has prompted a need to develop animal models of OUD that have both face and predictive validity. Oxycodone use in humans is more prevalent in women and leads to pronounced hyperalgesia and irritability during withdrawal. However, unclear is whether current animal models of oxycodone self-administration recapitulate these characteristics in humans.
OBJECTIVES: We assessed the face validity of a model of extended-access oxycodone self-administration in rats by examining the escalation of oxycodone intake and behavioral symptoms of withdrawal, including irritability-like behavior and mechanical nociception, in male and female Wistar rats.
RESULTS: Both male and female rats escalated their oxycodone intake over fourteen 12-h self-administration sessions. After escalation, female rats administered more drug than male rats. No differences in plasma oxycodone levels were identified, but males had a significantly higher level of oxycodone in the brain at 30 min. Extended access to oxycodone significantly decreased aggressive-like behavior and increased defensive-like behaviors when tested immediately after a 12-h self-administration session, followed by a rebound increase in aggressive-like behavior 12 h into withdrawal. Tests of mechanical nociception thresholds during withdrawal indicated pronounced hyperalgesia. No sex differences in irritability-like behavior or pain sensitivity were observed.
CONCLUSIONS: The present study demonstrated the face validity of the extended access model of oxycodone self-administration by identifying sex differences in the escalation of oxycodone intake and pronounced changes in pain and affective states.

Entities:  

Keywords:  Aggression; Defensive; Hyperalgesia; Irritability; Opioid; Oxycodone; Pain; Self-administration; Sex differences; von Frey test

Mesh:

Substances:

Year:  2020        PMID: 32114633      PMCID: PMC7269712          DOI: 10.1007/s00213-020-05479-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  75 in total

1.  Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia.

Authors:  Paula E Park; Joel E Schlosburg; Leandro F Vendruscolo; Gery Schulteis; Scott Edwards; George F Koob
Journal:  Addict Biol       Date:  2013-12-13       Impact factor: 4.280

2.  Voluntary induction and maintenance of alcohol dependence in rats using alcohol vapor self-administration.

Authors:  Giordano de Guglielmo; Marsida Kallupi; Maury D Cole; Olivier George
Journal:  Psychopharmacology (Berl)       Date:  2017-03-24       Impact factor: 4.530

3.  Nociceptin attenuates the escalation of oxycodone self-administration by normalizing CeA-GABA transmission in highly addicted rats.

Authors:  Marsida Kallupi; Lieselot L G Carrette; Jenni Kononoff; Leah C Solberg Woods; Abraham A Palmer; Paul Schweitzer; Olivier George; Giordano de Guglielmo
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-13       Impact factor: 11.205

4.  CRF1 Receptor-Dependent Increases in Irritability-Like Behavior During Abstinence from Chronic Intermittent Ethanol Vapor Exposure.

Authors:  Adam Kimbrough; Giordano de Guglielmo; Jenni Kononoff; Marsida Kallupi; Eric P Zorrilla; Olivier George
Journal:  Alcohol Clin Exp Res       Date:  2017-09-22       Impact factor: 3.455

5.  Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial.

Authors:  Sudie E Back; Rebecca L Payne; Amy Herrin Wahlquist; Rickey E Carter; Zachary Stroud; Louise Haynes; Maureen Hillhouse; Kathleen T Brady; Walter Ling
Journal:  Am J Drug Alcohol Abuse       Date:  2011-09       Impact factor: 3.829

6.  Alterations of expression of inflammation/immune-related genes in the dorsal and ventral striatum of adult C57BL/6J mice following chronic oxycodone self-administration: a RNA sequencing study.

Authors:  Yong Zhang; Yupu Liang; Orna Levran; Matthew Randesi; Vadim Yuferov; Connie Zhao; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2017-06-26       Impact factor: 4.530

Review 7.  Opioid antagonists with minimal sedation for opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2017-05-29

8.  Extended access to nicotine leads to a CRF1 receptor dependent increase in anxiety-like behavior and hyperalgesia in rats.

Authors:  Ami Cohen; Jennifer Treweek; Scott Edwards; Rodrigo Molini Leão; Gery Schulteis; George F Koob; Olivier George
Journal:  Addict Biol       Date:  2013-07-22       Impact factor: 4.280

Review 9.  Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations.

Authors:  Larry F Chu; Martin S Angst; David Clark
Journal:  Clin J Pain       Date:  2008 Jul-Aug       Impact factor: 3.442

10.  Dopamine D3 Receptor Antagonism Reverses the Escalation of Oxycodone Self-administration and Decreases Withdrawal-Induced Hyperalgesia and Irritability-Like Behavior in Oxycodone-Dependent Heterogeneous Stock Rats.

Authors:  Giordano de Guglielmo; Marsida Kallupi; Sharona Sedighim; Amy H Newman; Olivier George
Journal:  Front Behav Neurosci       Date:  2020-01-14       Impact factor: 3.558

View more
  9 in total

1.  Chronic voluntary caffeine intake in male Wistar rats reveals individual differences in addiction-like behavior.

Authors:  Christine H Lee; Olivier George; Adam Kimbrough
Journal:  Pharmacol Biochem Behav       Date:  2020-02-24       Impact factor: 3.533

2.  Increased heroin intake and relapse vulnerability in intermittent relative to continuous self-administration: Sex differences in rats.

Authors:  Ginevra D'Ottavio; Ingrid Reverte; Davide Ragozzino; Maria Meringolo; Michele Stanislaw Milella; Fernando Boix; Marco Venniro; Aldo Badiani; Daniele Caprioli
Journal:  Br J Pharmacol       Date:  2022-01-05       Impact factor: 9.473

3.  The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice.

Authors:  Julien C Dodu; Rebecca K Moncayo; M Imad Damaj; Joel E Schlosburg; Hamid I Akbarali; Lesley D O'Brien; Debra A Kendall; Zhixing Wu; Dai Lu; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2021-10-08       Impact factor: 4.402

4.  Paradoxical changes in brain reward status during oxycodone self-administration in a novel test of the negative reinforcement hypothesis.

Authors:  Jacques D Nguyen; Yanabel Grant; Michael A Taffe
Journal:  Br J Pharmacol       Date:  2021-06-08       Impact factor: 9.473

5.  Escalated (Dependent) Oxycodone Self-Administration Is Associated with Cognitive Impairment and Transcriptional Evidence of Neurodegeneration in Human Immunodeficiency Virus (HIV) Transgenic Rats.

Authors:  Yu Fu; Irene Lorrai; Barry Zorman; Daniele Mercatelli; Chase Shankula; Jorge Marquez Gaytan; Celine Lefebvre; Giordano de Guglielmo; Hyunjae Ryan Kim; Pavel Sumazin; Federico M Giorgi; Vez Repunte-Canonigo; Pietro Paolo Sanna
Journal:  Viruses       Date:  2022-03-24       Impact factor: 5.818

Review 6.  A Glitch in the Matrix: The Role of Extracellular Matrix Remodeling in Opioid Use Disorder.

Authors:  Madelyn H Ray; Benjamin R Williams; Madeline K Kuppe; Camron D Bryant; Ryan W Logan
Journal:  Front Integr Neurosci       Date:  2022-06-09

7.  Establishment to measure oxycodone in plasma with liquid chromatography-tandem mass spectrometry.

Authors:  Suguru Ito; Masato Mori; Momoka Matsuo; Rio Yamasaki; Yasuhisa Oida; Midori Soda; Kiyoyuki Kitaichi
Journal:  Neuropsychopharmacol Rep       Date:  2022-06-11

Review 8.  Behavioral sex differences in cocaine and opioid use disorders: The role of gonadal hormones.

Authors:  Melissa C Knouse; Lisa A Briand
Journal:  Neurosci Biobehav Rev       Date:  2021-06-29       Impact factor: 9.052

9.  A buprenorphine-validated rat model of opioid use disorder optimized to study sex differences in vulnerability to relapse.

Authors:  Anousheh Bakhti-Suroosh; Eleanor Blair Towers; Wendy J Lynch
Journal:  Psychopharmacology (Berl)       Date:  2021-01-06       Impact factor: 4.415

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.